{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-135073","form_type":"8-K","ticker":"BBIO","cik":"0001743881","company_name":"BridgeBio Pharma, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.346322+00:00","generated_at":"2026-06-15T22:31:38.625761+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BridgeBio Q1 net loss narrows to $140M ($0.92 loss per share); cash $467M after $150M offering","bullets":["Net loss attributable to common stockholders $140.2M ($0.92 diluted EPS) vs $196.4M ($1.35) in Q1 2022; revenue $1.8M flat.","Operating expenses fell 27% YoY to $128.0M from $175.4M, reflecting cost restructuring and program reprioritization.","Cash, equivalents, marketable securities, and restricted cash $467.0M; includes $143M net from follow-on offering closed in March 2023.","Phase 3 ATTR-CM trial of acoramidis completed last patient last visit; topline month-30 data expected late July 2023.","Infigratinib (achondroplasia) Phase 2 Cohort 5 showed +3.03 cm/yr annualized height velocity; 80% responders; Phase 3 run-in started."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-135073","json":"https://secwatch.observer/filing/0001193125-23-135073.json","markdown":"https://secwatch.observer/filing/0001193125-23-135073.md","text":"https://secwatch.observer/filing/0001193125-23-135073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523135073/0001193125-23-135073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1743881/000119312523135073/d207223d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:31:38.625761+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}